1.

Use of thyroid function tests in urine: a position statement of the Belgian Thyroid Club.

2.

Use of thyroid function tests in urine: a position statement of the Belgian Thyroid Club.

3.

Use of thyroid function tests in urine: a position statement of the Belgian Thyroid Club.

4.

Use of thyroid function tests in urine: a position statement of the Belgian Thyroid Club.

5.

Use of thyroid function tests in urine: a position statement of the Belgian Thyroid Club.

6.

Use of thyroid function tests in urine: a position statement of the Belgian Thyroid Club.

7.

Use of thyroid function tests in urine: a position statement of the Belgian Thyroid Club.

8.

Use of thyroid function tests in urine: a position statement of the Belgian Thyroid Club.

9.

Use of thyroid function tests in urine: a position statement of the Belgian Thyroid Club.

1.

Daly/Cost comparison in the management of peripheral arterial disease at 17 Belgian hospitals.

2.

Daly/Cost comparison in the management of peripheral arterial disease at 17 Belgian hospitals.

3.

Daly/Cost comparison in the management of peripheral arterial disease at 17 Belgian hospitals.

4.

Daly/Cost comparison in the management of peripheral arterial disease at 17 Belgian hospitals.

5.

Daly/Cost comparison in the management of peripheral arterial disease at 17 Belgian hospitals.

6.

Daly/Cost comparison in the management of peripheral arterial disease at 17 Belgian hospitals.

7.

Daly/Cost comparison in the management of peripheral arterial disease at 17 Belgian hospitals.

8.

Daly/Cost comparison in the management of peripheral arterial disease at 17 Belgian hospitals.

9.

Daly/Cost comparison in the management of peripheral arterial disease at 17 Belgian hospitals.

1.

Nationwide quality assurance of high-throughput diagnostic molecular testing during the SARS-CoV-2 pandemic: role of the Belgian National Reference Centre.

2.

Nationwide quality assurance of high-throughput diagnostic molecular testing during the SARS-CoV-2 pandemic: role of the Belgian National Reference Centre.

3.

Nationwide quality assurance of high-throughput diagnostic molecular testing during the SARS-CoV-2 pandemic: role of the Belgian National Reference Centre.

4.

Nationwide quality assurance of high-throughput diagnostic molecular testing during the SARS-CoV-2 pandemic: role of the Belgian National Reference Centre.

5.

Nationwide quality assurance of high-throughput diagnostic molecular testing during the SARS-CoV-2 pandemic: role of the Belgian National Reference Centre.

6.

Nationwide quality assurance of high-throughput diagnostic molecular testing during the SARS-CoV-2 pandemic: role of the Belgian National Reference Centre.

7.

Nationwide quality assurance of high-throughput diagnostic molecular testing during the SARS-CoV-2 pandemic: role of the Belgian National Reference Centre.

8.

Nationwide quality assurance of high-throughput diagnostic molecular testing during the SARS-CoV-2 pandemic: role of the Belgian National Reference Centre.

9.

Nationwide quality assurance of high-throughput diagnostic molecular testing during the SARS-CoV-2 pandemic: role of the Belgian National Reference Centre.

1.

Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club

2.

Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club

3.

Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club

4.

Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club

5.

Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club

6.

Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club

1.

Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of t...

2.

Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of t...

3.

Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of t...

4.

Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of t...

5.

Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of t...

6.

Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of t...

1.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

2.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

3.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

4.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

5.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

6.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

7.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

8.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

9.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

1.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

2.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

3.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

4.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

5.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

6.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

7.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

8.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

9.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

1.

Belgian end-of-life care study did not include French-speaking units.

2.

Belgian end-of-life care study did not include French-speaking units.

3.

Belgian end-of-life care study did not include French-speaking units.

4.

Belgian end-of-life care study did not include French-speaking units.

5.

Belgian end-of-life care study did not include French-speaking units.

1.

Does the Belgian law legalising euthanasia for minors really address the needs of life-limited children?

2.

Does the Belgian law legalising euthanasia for minors really address the needs of life-limited children?

3.

Does the Belgian law legalising euthanasia for minors really address the needs of life-limited children?

4.

Does the Belgian law legalising euthanasia for minors really address the needs of life-limited children?

5.

Does the Belgian law legalising euthanasia for minors really address the needs of life-limited children?

1.

Trends and predictors of transmitted drug resistance (TDR) and clusters with TDR in a local Belgian HIV-1 epidemic

2.

Trends and predictors of transmitted drug resistance (TDR) and clusters with TDR in a local Belgian HIV-1 epidemic

3.

Trends and predictors of transmitted drug resistance (TDR) and clusters with TDR in a local Belgian HIV-1 epidemic

4.

Trends and predictors of transmitted drug resistance (TDR) and clusters with TDR in a local Belgian HIV-1 epidemic

5.

Trends and predictors of transmitted drug resistance (TDR) and clusters with TDR in a local Belgian HIV-1 epidemic